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Abstract
Cystic fibrosis (CF) is a life-limiting, monogenic disorder
characterized by chronic sinopulmonary and gastrointestinal
involvement. Progressive pulmonary disease leads to death in the
majority of patients. Despite its well-defined molecular basis related
to defects in the cystic fibrosis transmembrane conductance
regulator anion transport channel, there are large gaps in our
understanding of the origin of CF lung disease. Disease has been
shown to be present in infancy, and there is mounting evidence that
abnormalities begin in utero. Heterogeneity of clinical presentations
and severity suggest that many factors involved in lung disease
have yet to be fully elucidated. Although new advances in therapeutic
treatments have shown promise in delaying disease progression, the
prevention of pulmonary disease at its origin (primary prevention)
should be a key goal of CF care. The objective of this workshopwas to
(1) review our understanding of the origins of CF lung disease, (2)
determine gaps in the knowledge base that are most significant and
most likely to enable prevention of CF lung disease, and (3)
prioritize new research questions thatwill promote pulmonaryhealth
in both CF and other childhood lung diseases. The goal of this report
is to provide recommendations for future research that will
improve our understanding of pulmonary development in health and
disease, improve outcome measures and biomarkers for early lung
disease, and determine therapeutic targets and strategies to
prevent the development of lung disease in children with CF.
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Although cystic fibrosis (CF) has a well-
defined molecular basis, debate continues as
to when and how CF lung disease first
develops, particularly given the
heterogeneous nature of lung disease in this
population. The CF subgroup focused on
strategies to prevent development of
measurable CF lung disease and the
prioritization of research strategies to
delineate and measure factors leading to
disease development.
CF is the most common life-shortening
autosomal recessive disease of whites. It
occurs in approximately 1 in 3,500 live
births and is characterized by chronic
sinopulmonary and gastrointestinal
involvement (1). Although the life
expectancy of a child born with CF has
gradually improved, the mortality rate
remains virtually unchanged, typically due
to progressive airway disease. Mutations
in the cystic fibrosis transmembrane
conductance regulator (CFTR), a gene that
encodes an anion transport protein present
in the epithelial cell membrane, lead to the
manifestations of CF. Defective Cl2 and
HCO3 transport, coupled with altered
regulation of Na1 transport, lead to
decreased airway surface liquid and
increased mucus viscosity, thereby
impeding mucociliary clearance and
promoting mucus stasis (2, 3). Mucus
stasis, likely coupled with other host
defense defects, leads to chronic and
progressive inflammation, infection,
airways obstruction, bronchiectasis, and
deterioration of pulmonary function
(Figure 1).
Variability in the rate of progression
of CF lung disease occurs even among
individuals carrying identical CFTR
mutations (4, 5). Affected twin analysis
indicates genetic modifiers independent of
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CFTR account for approximately half of the
variation in lung function, with the
remainder attributed to environmental
exposures and stochastic effects (6, 7). A
number of replicated non-CFTR genetic
modifiers of CF lung disease severity have
been identified, some of which are
associated with inflammation (4, 8). The
neutrophilic inflammatory response to
chronic infection in CF is both protective
and destructive, as inflammation may
further worsen mucociliary clearance or
itself cause airway damage (Figure 1) (9, 10).
Poor nutrition is linked to impaired
pulmonary growth, greater morbidity, and
increased mortality, but may also impair
host defense (11). Viral and bacterial
infections are clearly associated with
progression of CF lung disease (12–14). New
data on the lung microbiota continue to
highlight the complex interactions between
infectious exposures and the host lung (15).
CF lung disease can present in infancy
(16) and may be highly heterogeneous
within the lung of an individual subject
with CF (17). Measurable differences in
infant lung function between children with
CF and healthy control subjects are evident
as early as 6 to 12 months of age, and
focal areas of bronchiectasis, mucus
plugging, and air trapping may be evident
in the first year of life (18, 19). Animal
models suggest structural abnormalities in
the CF lung may occur in utero, and other
developmental defects may also be present.
In contrast, some individuals with CF may
not have measureable lung disease until
much later in life, emphasizing the variable
nature of the disease and fueling debate as
to when CF lung disease truly begins. One
could argue that disease begins at
conception, when a sperm and egg combine
to create an embryo with two deleterious
CFTR mutations. Because of the high
penetrance of disease-causing CFTR
mutations, we know that the child who
develops from this union will manifest
features of CF. From this perspective,
interventions before conception could be
considered as a form of primary prevention
of CF lung disease (Figure 2). Even though
genetic and molecular pathogenesis is well
understood, defining precisely when CF
lung disease begins remains challenging.
Does lung disease begin shortly after
conception? In utero or after birth, when
defective ion transport becomes manifest?
When the affected child develops functional
or structural changes in the lung, or when
the child becomes symptomatic? Or does
lung disease begin at some other arbitrarily
defined point?
Diagnosis of CF in infancy is made by
a combination of positive newborn screen
and either positive sweat chloride testing or
intermediate sweat chloride testing with
two disease-causing mutations in CFTR;
diagnosis in the nonnewborn screen
population relies on sweat chloride testing,
genetic testing, and clinical symptoms
and/or family history (20). Despite these
(typically) straightforward guidelines for
diagnosis of CF, definition of the definitive
starting point of CF lung disease is not
established and may vary from patient to
patient. Given that the majority of infants
with CF have some abnormalities noted (by
imaging, pulmonary function testing,
respiratory culture, or inflammatory
markers) by 6 to 12 months of age, our
group defined a window of intervention as
before 12 months of age or before the
presence of detectable disease by structural,
functional, or biochemical measures.
The clearest mechanism to prevent CF
lung disease, excluding in utero measures, is
to target intervention at the gene or gene
product level (what we will define as
primary risk factors) as early in life as
possible. This strategy might include
Figure 1. A conceptual framework for the progression of disruption of mucociliary clearance leading to intermittent, then chronic, infection and
inflammation in the lungs of patients with cystic fibrosis. mac = macrophage; NE = neutrophil elastase, pmn = neutrophil.
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interventions directed toward the CFTR
gene, genetic modifiers, or protein function.
Barring complete recovery or restoration of
CFTR function, interventions targeted at
secondary risk factors will continue to be
important in prevention of CF lung disease.
Although many molecular-based therapies
are available or currently under
investigation, these agents have mostly been
studied in older children and adults. Few
interventional studies have been performed
in the preschool CF population, and
there are virtually no data on treatment
effects in the first year of life.
Priority Areas for
Future Research
Defining the Epidemiology of CF in
the Age of Genetic Screening
A discussion of primary prevention of lung
disease in single-gene disorders such as CF
would be incomplete if we did not consider
reproductive options available to carriers.
Screening of individuals for CF carrier status
has occurred in the United States for 2
decades, and there are a variety of
reproductive alternatives available to carrier
couples identified in the prepregnancy
phase, ranging from egg or sperm donation
to preimplantation genetic diagnosis (21)
(Figure 2). The vast majority of CF carrier
screening is now offered postconception
to the pregnant mother. CF carrier
screening programs have been reported for
some states, but regional and national
assessments of program impact are lacking.
Another gap in our understanding is
whether CF carrier screening has changed
the incidence of CF or CFTR allele
distribution in the United States, both of
which have been reported in smaller studies
from individual states in the United States
and in European countries (22, 23).
National data from the CF Foundation
Patient Registry does not reflect a notable
decrease in incidence of CF over the past
decade, possibly because many couples are
opting to continue affected pregnancies to
term. Considering that more than 1 million
individuals are screened for CF each year,
it is remarkable that we do not have
a comprehensive assessment of the
screening effect.
Potential research questions:
d What is the effectiveness of carrier
screening, and has it affected the
incidence of CF, distribution of CFTR
mutations, or management of newborns
known to have CF before birth?
d Are there socioeconomic, geographic, or
cultural trends to the delivery of CF
carrier screening?
d How has carrier screening affected use of
preconceptual options by at-risk couples?
Would the decision process of carrier
couples change if effective molecular-
based therapy for CF were available?
Gene/Protein/Molecular Interactions
If lung function is normal in utero, then
implementation of therapies targeting
CFTR at birth, before the onset of
symptoms, provides a critical window for
intervention strategies (Figure 1). Even if
lung development is altered in utero,
restoration of CFTR function as soon as
possible would provide the greatest
opportunity for prevention of chronic lung
disease. Therapies that are of immediate
consideration for newborns with CF are
those targeted to the basic defect, including
nutritional interventions that improve
growth and lung development. Given the
proven efficacy of ivacaftor in older patients
with the p.Gly551Asp (G551D) mutation, it
would be a high priority to assess feasibility
and safety of administering ivacaftor to
newborns with G551D. Correction of
mutant CFTR would be the optimal therapy
for newly diagnosed patients, but some
forms of mutant CFTR are challenging to
treat. Thus, resources should be focused on
correction of all forms of mutant CFTR. In
addition, given recent advances toward
in situ genetic correction, such approaches
should remain an active area of research. It
is also possible that treatments that have
limited efficacy in older children and adults
might prove to be of greater efficacy in
newborns or infants in whom lung disease
is in the earliest phases. Examples include
agents broadly designed to restore mucus
clearance, novel ion transport regulators,
and mucolytic agents. Finally, with the
advent of technologies that can interrogate
the entire human genome, it has been
possible to localize genes other than CFTR
that influence outcome. Some of these genes
are likely to encode therapeutic targets for
which drugs are already available.
Treatment of CF at the earliest point
requires newborn screening, which allows
the opportunity for early intervention.
Figure 2. A conceptual framework for early intervention in and primary prevention of cystic fibrosis lung disease. Items highlighted in blue are diagnostic




Normal and CF data sets with biomarkers
for neonates and children are required for
early intervention studies.
Potential research questions:
d What are the efficacy and safety of novel
and existing agents targeting molecular
defects associated with CF in infants?
d What are the safety and efficacy of novel
and existing agents targeting downstream
consequences of CFTR dysfunction (e.g.,
restoration of mucus clearance, ion defects,
etc.) used in the first 3 months of life?
d Can individualized care of patients with
CF be facilitated by genome sequencing
to allow determination of the status of
known and newly discovered genetic
modifiers?
Defining the Early Infectious Milieu
and Implications of Early Infection
Ineffective mucociliary clearance and
defective innate defenses allow bacterial
infection to become established in the CF
airway (24, 25) (Figure 1). Early acquisition
of pathogenic bacteria and chronic
infection are associated with increased
morbidity and mortality in CF (26, 27).
Despite aggressive antibiotic treatment for
exacerbations, lung disease persists after
treatment (28). Management of these early
infections has included prophylaxis and
eradication protocols; however,
bronchiectasis may be present in the
absence (or before detection) of these
characteristic organisms, suggesting that
our understanding of the early microbiota
is limited and other infections, such as
viruses or anaerobes, could have a
significant role in initiating CF lung
disease.
The polymicrobial nature of the CF
airway has recently been highlighted (15,
29); its diversity appears to be high in the
older pediatric population and decrease
over time in adults. It is unclear whether
current antibiotic regimens produce the
narrowing of microbiota diversity. Changes
in microbial diversity in the gastrointestinal
tract of the CF population have similarly
been linked to respiratory disease. More
studies are needed to understand the effect
of these complex bacterial communities.
Respiratory virus infections play
a significant role in pulmonary
exacerbations and can lead to morbidity in
children with CF. Studies in the CF
population have linked infection with
established respiratory viruses to clinical
deterioration. These viruses injure the
airway, induce local inflammatory responses,
and may produce airway surface dehydration
and mucus stasis. These effects render the
lung more susceptible to infection and
exaggerate the host inflammatory response
by concentrating chemokines and cytokines
on the airway surface (30). Viral infections in
children with CF tend to be more severe,
have a longer duration than in children
without CF (26, 31), and have been linked to
reduced lung function (32, 33). The precise
role of early viral infections in the
development of pulmonary disease in CF
has yet to be defined.
Potential research questions:
d How do microbiota develop in the
normal and CF airway and evolve over
time? How does the basic CF defect lead
to alterations in the airway microbiota?
Does diversity of the microbiota protect
against infections and pulmonary
deterioration? Does the microbiota
modulate the immune system? What is
the impact of pathogen-specific
interventions on airway microbiota?
d What are the relationships between
intestinal and respiratory microbiota?
How does infant nutritional status and
diet (e.g., breast milk) affect the bacterial
flora at both sites? How does infant
nutritional status affect pulmonary health?
d What are the importance and impact of
viral infections on early CF lung disease?
What is the best means of monitoring
the airway microbial community and
assessing change over time?
Inflammatory Background
and Interventions
Normal airways are protected from
infection by a complicated host defense
system. The respiratory epithelium is the
first line of defense of the airways. Mucus,
rich with proteolytic and antibacterial
enzymes, is constantly produced by the
epithelium. It is cleared via the mucociliary
escalator, whose efficacy is dependent on
the interactions of cilia and the non-
Newtonian properties of mucus. Airway
macrophages complement epithelial
defenses, yet these multiple layers of
pulmonary defense are overwhelmed in
CF as lung disease develops (34, 35).
Inflammation in the CF airway begins
early in life and may occur independent of
infection. Relatively minor infection may
induce an exaggerated and prolonged
inflammatory response in the CF lung
(Figure 1). Infants with CF and uninfected
control subjects have been shown to have
similar bronchoalveolar lavage (BAL)
profiles (10, 36). At some point, the airway
is unable to prevent infection, which
becomes persistent, a cardinal feature of
CF. The resultant inflammatory response
contributes to the progressive, suppurative
pulmonary disease in CF. Neutrophils are
the prominent inflammatory cell in the
lungs of patients with CF, even in mild
Table 1. Primary prevention of cystic
fibrosis lung disease: research priorities
Epidemiology of CF in the age of genetic
screening
Effectiveness of carrier screening, and
effect on distribution of CFTR mutations
Socioeconomic, geographic, and cultural
trends in the delivery of CF carrier
screening
Effect of screening on use of
preconceptual options by at-risk
couples
Gene/molecular/protein interactions
Efficacy and safety of agents targeting
CFTR molecular defects in the infant
population
Efficacy and safety of agents targeting
downstream effects of CFTR
dysfunction in infants
Feasibility of individualized care via
genome sequencing and DNA banking
Implications of early infection
Development/evolution of microbiota in
normal and CF airways, and impact of
diversity
Relationship between intestinal and
respiratory microbiota
Importance and impact of viral infections
on early CF lung disease
Inflammatory background and interventions
The CF inflammatory response—
appropriate or disproportionate
Role of inflammation and sterile
mucostasis in the infant lung
Effect of antiinflammatory therapies on
prevention of CF lung disease
Outcome measure and biomarker
development
Best outcome measures for infant trials—
structural, functional, biomarkers,
patient-reported outcomes
Establish normative values, applicability,
and usefulness of noninvasive testing
techniques
Investigate association of different
outcome measures
Definition of abbreviations: CF = cystic fibrosis;
CFTR = cystic fibrosis transmembrane
conductance regulator.
NHLBI WORKSHOP
S164 AnnalsATS Volume 11 Supplement 3| April 2014
 
disease (37). Neutrophils release DNA,
oxidants, and proteases into the airway,
which contribute to disease pathogenesis.
Inflammatory mediators, such as IL-8 and
various oxidants, have been found in high
concentration in BAL fluid, even in infants
with normal lung function and without
apparent bacterial colonization (38), and
higher BAL fluid neutrophil concentrations
are associated with respiratory symptoms.
Neutrophil elastase in lavage fluid has been
shown to predict early bronchiectasis in
children with CF (39).
Dysregulated activity of transcription
factors may lead to a hyperinflammatory
phenotype of the CF airway epithelium, and
ceramide accumulation may induce
apoptosis with deposition of DNA in the
airway and increase bacterial adhesion in the
CF airway (40, 41). Misfolded CFTR, which
elicits the unfolded protein response,
may contribute to the inflammatory CF
phenotype in some patients (42). The
function of immune cells may be
dysregulated as well, and poor nutrition
may further impact the inflammatory
milieu (43, 44). Finally, experiments in
animal models suggest that mucostasis, in
the absence of bacterial infection, can be
proinflammatory (45), with increased
release of neutrophil chemotactic agents.
Potential research questions:
d Is the CF inflammatory response to
infection proportionate or excessive, and,
if the latter, is it related to epithelial or
immune cell dysfunction?
d What is the role of inflammation in the
lung of an infant with CF? How are
nutritional health, airway infections, and
inflammation related? What is the
relationship of “sterile” mucostasis to
lung inflammation? Are innate defenses
in the CF airway defective early in life?
d What is the effect of antiinflammatory
therapies on development of CF lung
disease? Do they prevent airways
destruction or irreversible disease? Do
antiinflammatory therapies change the
microbiota or innate defenses of the CF
lung? What is the best method for
measuring change in inflammation and
changes brought about by these agents?
Outcome Measure and
Biomarker Development
Pulmonary outcome measures specific to
early childhood and sufficiently sensitive to
detect early lung disease are lacking, not just
in CF, but for the infant population as
a whole. Early measures that predict disease
development are important as endpoints in
young, asymptomatic children and may
suggest therapeutic targets. The ideal outcome
measure should be simple to perform, feasible
across multiple sites, sensitive to early,
nonhomogeneous lung disease in CF, and
responsive to interventions. Further work is
needed to determine the usefulness of existing
outcome measures in the infant/preschool
population and to develop and validate
newer, more sensitive (to early lung disease)
or specific (to pulmonary disease) measures.
Given the challenges of studying this
population, an armamentarium of endpoints
will likely be needed (46).
Structural (imaging) and functional
measures currently available are hampered
by the requirement for sedation, limited
reference data, and radiation exposure.
Imaging measures that have been used in
infants include chest computed tomography
(CT), which is sensitive to the presence and
heterogeneity of early disease, and chest
radiographs, which have limited usefulness
in infants with presymptomatic disease (18,
39). Magnetic resonance imaging (MRI)
studies are emerging (47). Priorities for
further development include chest CT and
MRI, improved quantification of chest CTs,
hyperpolarized gas MRI (ventilation
scans), mucociliary clearance studies,
positron emission tomography with
fluorodeoxyglucose (PET-FDG), combined
MRI/PET, and g scintigraphy.
Physiologic measures used in recent
studies include infant pulmonary function
testing, inductance plethysmography,
oscillometry, and measurement of resistance
and compliance (28, 48). Multiple breath
washout (MBW) testing, which assesses
ventilation heterogeneity and may be especially
sensitive to early peripheral airways disease, is
being developed for the preschool population
at a few specialized centers (49). Challenges of
lung function testing in infants include
sedation, expense, limited reference data, and
technical expertise. Priorities for development
include MBW, with particular emphasis on
reference values, testing in infants, and
defining longitudinal and clinically significant
change; nonsedated physiologic testing; and
improvement of reference equations and
longitudinal data for all measures.
Currently available biomarkers for
infant pulmonary disease are predominantly
measured in BAL fluid, necessitating
sedation and an invasive procedure, and
include inflammatory markers, cell counts
and differential, and neutrophil elastase
(10). Future development of biomarkers
might focus on measures of CFTR function
(either airways specific or whole body),
serum or urine inflammatory markers,
bacterial-specific antibodies, mucin
concentrations and mucus biophysical
analyses, assessment of microbiome or total
lung bacterial burden, macrophage function
measurement, and noninvasive measures
(exhaled breath condensate, metabolomics).
Nutritional status may also be
considered an outcome measure, although
nutritional intervention is certainly believed
to be an important initial therapy in the
newborn with CF. Poor nutritional status
(particularly weight or weight-to-height
ratio) in infancy has been linked to lower
lung function later in life, and it has been
shown that infants with CF have lower birth
weights, on average, than infants without
CF. Thus, there may be a primary
prevention intervention that could focus on
nutrition as a means of improving
pulmonary health and could also use
nutritional status as an outcome measure.
Finally, the only currently available
patient- and parent-reported outcome
in CF, the CFQR (CF Questionnaire,
Revised), has recently been extended into
preschoolers (50). The CFQR needs further
development in infants, as do exacerbation
and symptom scores, and perhaps a more
sensitive tool specific to symptoms in
younger patients with mild symptoms.
Potential research questions:
d What are the best outcome measures for
clinical trials in infants with CF?
d How can normative values, applicability,
and usefulness of MBW and other
minimally invasive techniques be
improved and developed?
d How are different measures (e.g.,
biomarkers and physiologic measures,
infant pulmonary function tests, and
MBW), associated? Can a better
understanding of associations allow better
characterization of CF lung disease?
Overall Priorities for Research
The priorities for research outlined below
are, in large part, focused on studies that





testing in early childhood; determining the
role of microbiota in pulmonary health
(including relationships between the enteral
microbiome, nutrition, and respiratory
health); and linking mucus properties,
infections, and inflammation in early
childhood disease to structural and
functional changes in childhood and
beyond (Table 1). Of course, as the science
of CF lung disease progresses, these
priorities may need to be adjusted to reflect
new knowledge and developments.
Near-term priorities were chosen with
the goal of improving efficacy trials in the
infant/preschool age group, reflecting our
belief that defining more uniform study
populations and improving sensitivity and
accessibility of outcome measures in
heterogeneous lung disease will improve
early interventional trials.
d Establish uniform endotypes (genotype
and phenotype subpopulations) based on
a combination of genetics (CFTR and
modifiers), biomarkers, outcome
measures (including pulmonary function
and nutritional measures),
environmental exposures, mucus,
inflammatory, and microbiome measures
to allow for more targeted interventions
based on predicted disease course (e.g.,
early severe lung disease, early nutritional
issues, hyperinflammatory endotypes).
Use of endotypes may better demonstrate
efficacy of therapeutic interventions by
targeting specific populations with CF.
d Improve and broaden early and
noninvasive outcome measures available
for the study of pulmonary disease in
young children to strengthen our ability
to assess the impact of interventional
studies and compare with healthy control
subjects. These may include pulmonary
function, assessment of structural lung
disease, pulmonary-specific
inflammatory markers and other markers
of lung damage, and investigation of the
pulmonary microbiota.
B Improvement should include
determination of normative values
across ages, “normal” longitudinal
changes in both healthy subjects and
those with disease, and definition of
clinically significant change.
Long-term priorities reflect the goal of
eradicating CF lung disease by providing
personalized interventions for each patient
beginning at birth. These studies would use
outcome measures and target subjects based
on endotypes described above.
d Establish the effect of molecular, genetic,
or downstream (therapeutic)
interventions initiated in infancy on
preventing CF lung disease. Define
optimal timing of interventions in
infancy and determine the role for
prenatal screening in promoting
intervention at birth. Special
considerations include determination of
appropriate duration and interval of
treatments (to provide greatest clinical
benefits with fewest side effects and lowest
cost), identification of CF endotypes most
likely to benefit from specific
interventions, and detailed monitoring for
potential side effects. Outcomes to be
considered would include those listed
above. Longitudinal study will be
necessary, because demonstrable
differences in treatment groups may
require years of data collection.
B Determine the impact of CFTR
correctors and potentiators on the
prevention of CF lung disease when
treatment is initiated early, shortly
after diagnosis.
B Determine the impact of agents
designed to improve mucociliary
clearance (hypertonic saline, dornase-
alfa, N-acetylcysteine, mannitol) on
the prevention of detectable lung
disease in infants with CF.
B Determine the impact of
antiinflammatory agents
(azithromycin, ibuprofen) on the
prevention of lung disease in infants
with CF.
d Investigate the normal development of
the microbiota of the lung and the
impact of alterations in respiratory flora
on lung health in children with CF.
Summary
Great progress has been made in the past
quarter century in the understanding
and treatment of CF, with the potential to
slow progression of structural damage and
functional impairment beginning in the
first few months of life. This is reflected in
a steadily increasing median life expectancy
in patients with CF. Neonatal diagnosis,
early interventions, and newer mutation-
based treatment options have led some to
consider what was unthinkable only a few
years ago—primary prevention of CF
disease. To shift the treatment paradigm
for CF, however, we need to fully
understand the pathophysiological origins
of CF lung disease, identify relevant
biomarkers, and better define outcomes.
Primary prevention would profoundly
change the trajectory of CF lung disease
and improve the morbidity and mortality
of future children. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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